Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SKYE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSkye Bioscience reprices 2.4M underwater stock options to $0.615, appoints fractional CFO
Filed April 3, 2026 · Period ending March 31, 2026 · ~1 min read
Key Changes
-
high
Company repriced all employee stock options granted before Dec 2025 to $0.615/share (current stock price), affecting 2.4M shares with original exercise prices ranging from $1.055 to $14.56. CEO received repricing on 1.1M options (46% of total), originally priced up to $14.56.
Item 5.02: Option Repricing verify on EDGAR → -
high
Board justified repricing as retention tool to avoid additional dilution or cash compensation costs, signaling concern about employee departures and limited financial flexibility to offer alternative incentives.
Item 5.02: Board Rationale verify on EDGAR → -
medium
Appointed John P. Sharp as CFO through consulting firm at $25,600/month for up to 64 hours (fractional arrangement), rather than as full-time employee. Sharp has 30+ years finance experience including CFO roles at PhaseBio and Ligand Pharmaceuticals.
Item 5.02: CFO Appointment verify on EDGAR → -
medium
Fractional CFO structure suggests cost management priorities and potentially limited executive time commitment compared to traditional full-time C-suite role.
Item 5.02: Master Services Agreement verify on EDGAR →
Summary
Skye Bioscience took two significant actions on March 31, 2026, both reflecting financial constraints. The company repriced 2.4 million underwater stock options to $0.615 per share—the current trading price—affecting all employees with grants before year-end 2025.
CEO Punit Dhillon's 1.1 million repriced options represent nearly half the total, with original exercise prices as high as $14.56, indicating the stock has fallen dramatically from prior levels. The board framed this as a retention measure to avoid further dilution or cash outlays, suggesting concern about talent flight and limited resources for alternative compensation. Simultaneously, the company appointed John P.
Sharp as CFO through a consulting arrangement rather than direct employment. Sharp will work up to 64 hours monthly for $25,600 through Lohman & Associates, a fractional executive model that reduces fixed costs but may limit CFO availability. While Sharp brings solid credentials from prior biotech CFO roles, the part-time structure is unusual for a public company and reinforces the cost-conscious posture. Retail investors should monitor whether the repricing stabilizes the team or signals deeper retention issues, and watch for any SEC filings indicating insider selling post-repricing. The fractional CFO arrangement warrants attention to financial reporting quality and timeliness given limited executive bandwidth.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · view on EDGAR →
Name and Position | Total Repriced Options | Original Exercise Price of Repriced Options | Punit Dhillon | President and Chief Executive Officer | 1,103,959 | $2.89 to $14.56 | Tuan Diep | Chief Operating Officer | 396,295 | $2.89 to $14.56
CEO Punit Dhillon received repricing on 1,103,959 options (46% of total repriced) with original exercise prices of $2.89 to $14.56. COO Tuan Diep received repricing on 396,295 options with the same original price range. Both executives' options were significantly underwater before the repricing.
Added in current filing · verify on EDGAR →
On March 31, 2026, the Board appointed John P. Sharp as the Chief Financial Officer of the Company (“CFO”), effective immediately. Mr. Sharp will also serve as the Company’s principal financial and accounting officer, effective March 31, 2026.
John P. Sharp, age 61, was appointed CFO effective March 31, 2026. He brings over 30 years of finance experience and previously served as CFO at multiple biopharmaceutical companies including PhaseBio Pharmaceuticals (Nasdaq: PHAS) and Ligand Pharmaceuticals (Nasdaq: LGND).
Added in current filing · verify on EDGAR →
In connection with the appointment of Mr. Sharp, on March 31, 2026, the Company entered into a Master Services Agreement (the “Master Services Agreement”)with L&A, pursuant to which L&A agreed to provide accounting, business strategy and consulting, fractional chief financial officer services and human resources consulting services to the Company, as more specifically set forth in one or more Statements of Work (“SOWs”) issued under the Master Services Agreement and signed by the Company and L&A, including Scope of Work Number One (“SOW Number One”), which sets forth the services to be provided by Mr. Sharp as CFO. Pursuant to the Master Services Agreement and SOW Number One, L&A will bill the Company at a flat rate of $25,600 for up to 64 hours per month of the services of Mr. Sharp as CFO, with any services above 64 hours in a month, any out-of-scope services, any travel or lodging expense, any technology or administrative surcharge, and any change to the hourly rates set forth therein to be approved in writing by the parties.
Rather than hiring Sharp as a direct employee, the company engaged him through Lohman & Associates consulting firm at $25,600 per month for up to 64 hours of CFO services. This fractional CFO arrangement suggests cost management priorities and potentially limited CFO time commitment compared to a full-time executive role.
Event · Item 9.01 — Financial Statements and Exhibits
Skye Bioscience entered into a Master Services Agreement with Lohman & Associates, Inc. on March 31, 2026.
Added in current filing · verify on EDGAR →
Master Services Agreement, dated March 31, 2026, by and between Skye Bioscience, Inc. and Lohman & Associates, Inc.
The company has entered into a Master Services Agreement with Lohman & Associates, Inc. effective March 31, 2026. The 8-K does not provide details about the scope, terms, or financial impact of this agreement, only that it was executed and is being filed as an exhibit.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify